Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 5/2016

01-10-2016 | Current Opinion

Genomic Testing in The Paediatric Population: Ethical Considerations in Light of Recent Policy Statements

Authors: Ainsley J. Newson, Lisa Schonstein

Published in: Molecular Diagnosis & Therapy | Issue 5/2016

Login to get access

Abstract

Genomic testing is rapidly becoming established in clinical practice and research. In this paper we consider the ethical issues arising in genomic testing in children, focusing on the clinical context. After describing how genomics can be said to depart from genetics in ethically relevant ways, we introduce two case studies involving ethical issues in paediatric genomic testing. We then summarise and critically engage with recent professional statements regarding genomic testing in children; notably the 2015 position statement from the American Society for Human Genetics. To provide a conceptual framework for these debates, we then synthesise recent bioethics literature regarding appropriate concepts to use when making decisions regarding children, and applying them to genomic testing. We recommend an approach to genomic testing in children that is child-focused and flexibly applied, driven by a core clinical question. Finally, we examine the role that age and emerging capacity should play in these debates.
Footnotes
1
We focus our discussion on the use of genomic testing in circumstances when a test is being considered to answer a clinical question relating to a child’s diagnosis or prognosis. We do not discuss single-gene genetic testing or pharmacogenomics; nor do we consider the use of genomic testing in ‘first-line’ newborn screening or its provision direct to consumers without clinical recommendation.
 
2
In this paper we use the term ‘children’ to mean any person under the age of 16. In Sect. 5 we consider the impact that a child’s developing autonomy and sense of self should have on decisions regarding genomic testing.
 
3
We interpret ‘genomic testing’ to include approaches such as whole genome sequencing, whole exome sequencing and panel testing; or other approaches that exploit massively parallel DNA sequencing techniques.
 
4
The ASHG and AAP/ACMG may reply to this by contending that their position statements are not ethically normative, merely directions for practice and research. However, they are written using language that could be interpreted as having normative intention, such as the use of ‘should’ and ‘must’. The statements also explicitly reference ethical issues.
 
5
It could be argued that acting in a family’s best interests could also be said to be an action in a child’s best interests too. We address this point later in the paper.
 
6
This level is explained further by Jonas, who takes a welfare-based account of interests; following legal philosopher Joel Feinberg. One description of an acceptable level of interest-fulfillment is one that meets minimal welfare considerations.
 
7
Alongside the scenarios we discuss, other situations may also arise in which a child who is capable of engaging in decision-making expresses an opinion regarding testing that diverges from that of her carers. Such a discussion is beyond the scope of this paper.
 
Literature
1.
Ross LF, Saal HM, David KL, Anderson RR. American Academy of Pediatrics, American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet Med. 2013;15(3):234–45.CrossRefPubMed
2.
3.
4.
Botkin J, Belmont J, Berg J, Berkman B, Bombard Y, Holm I, et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 2015;97(1):6–21.CrossRefPubMedPubMedCentral
5.
Biesecker BB, Klein W, Lewis KL, Fisher TC, Wright MF, Biesecker LG, et al. How do research participants perceive “uncertainty” in genome sequencing? Genet Med. 2014;16(12):977–80.CrossRefPubMedPubMedCentral
6.
7.
American Society of Human Genetics, American College of Medical Genetics. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet. 1995;57(5):1233–41.
8.
American Academy of Pediatrics, Committee on Bioethics, Committee on Genetics, American College of Medical Genetics, Genomics Social Ethical and Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131(3):620–2.CrossRef
9.
Wilfond B, Ross LF. From genetics to genomics: ethics, policy, and parental decision-making. J Pediatr Psychol. 2009;34(6):639–47.CrossRefPubMed
10.
Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–74.CrossRefPubMedPubMedCentral
11.
12.
Hardart GE, Chung WK. Genetic testing of children for diseases that have onset in adulthood: the limits of family interests. Pediatrics. 2014;134(Suppl 2):S104–10.CrossRefPubMedPubMedCentral
13.
Feinberg J. The child’s right to an open future. In: Aiken W, LaFollette H, editors. Whose child? Children’s rights, parental authority, and state power. Totowa: Littlefield, Adams and Company; 1980. p. 124–53.
14.
15.
Edwards KT, Deans Z. Empirical ethics and the role of the professional ethicist in public policymaking. In: Ives J, Dunn M, Cribb A, editors. Interdisciplinary and empirical ethics: practical and theoretical perspectives. Cambridge: Cambridge University Press; 2016 (in press).
16.
Blustein J. Parents and children: the ethics of the family. New York: Oxford University Press; 1982.
17.
Carbone J. Legal applications of the “best interest of the child” standard: judicial rationalization or a measure of institutional competence? Pediatrics. 2014;134(Suppl 2):S111–20.CrossRefPubMed
18.
Ross LF. Predictive genetic testing of children and the role of the best interest standard. J Law Med Ethics. 2013;41(4):899–906.CrossRefPubMed
19.
Diekema DS. Parental refusals of medical treatment: the harm principle as threshold for state intervention. Theor Med Bioeth. 2004;25(4):243–64.CrossRefPubMed
20.
Birchley G. Harm is all you need? Best interests and disputes about parental decision-making. J Med Ethics. 2016;42(2):111–5.CrossRefPubMed
21.
Gillam L. The zone of parental discretion: an ethical tool for dealing with disagreement between parents and doctors about medical treatment for a child. Clin Ethics. 2016;11(1):1–8.CrossRef
22.
23.
24.
Haga SB, Terry SF. Ensuring the safe use of genomic medicine in children. Clin Pediatr. 2009;48(7):703–8.CrossRef
25.
May T, Zusevics KL, Strong KA. On the ethics of clinical whole genome sequencing of children. Pediatrics. 2013;132(2):207–9.CrossRefPubMed
26.
Metadata
Title
Genomic Testing in The Paediatric Population: Ethical Considerations in Light of Recent Policy Statements
Authors
Ainsley J. Newson
Lisa Schonstein
Publication date
01-10-2016
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 5/2016
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-016-0210-7

Other articles of this Issue 5/2016

Molecular Diagnosis & Therapy 5/2016 Go to the issue

Short Communication

Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia

Original Research Article

Utility of Hepatocyte Growth Factor as a Biomarker for Early Diagnosis of Pulmonary Artery Hypertension

Review Article

Liquid Biopsies in Oncology and the Current Regulatory Landscape

Review Article

The Future of Digital Polymerase Chain Reaction in Virology

Original Research Article

Impacts of TNF-LTA SNPs/Haplotypes and Lifestyle Factors on Oral Carcinoma in an Indian Population

Review Article

Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits